Relationship between triglyceride-glucose index and postoperative prognosis of patients with renal cell carcinoma

doi:10.3877/cma.j.issn.1674-3253.2025.04.016

Abstract

Abstract:

Objective

To investigate the correlation between triglyceride glucose (TyG) index and the prognosis of postoperative renal cell carcinoma patients.

Methods

A retrospective analysis was conducted on the clinical data of 108 patients with renal cell carcinoma who underwent surgical treatment at the Second People's Hospital of Huai'an City from January 2019 to January 2022. Kaplan-Meier method and Cox proportional hazards regression model were used to analyze the prognosis of the patients. Calculate the TyG index, obtain patient prognosis information through follow-up, and use Pearson correlation analysis to examine the relationship between TyG index and overall survival(OS) of patients.

Results

The differences in fasting blood glucose (FBG), triglycerides (TG), insulin levels (INS), creatinine (Cr), and other parameters among patients with different TyG index levels were statistically significant (P<0.05). After a follow-up of 49(35, 60) months postoperatively, 28 out of 108 patients with renal cell carcinoma died (25.93%), survived (74.07%), and had a median OS of 48 (34, 60) months. The low TyG group died in 6 cases (11.76%), survived in 45 cases (88.24%), had a median OS of 45 (33, 58) months, the medium TyG group died in 10 cases (25.64%), survived in 29 cases (74.36%), had a median OS of 40 (30, 56) months, the high TyG group died in 12 cases (66.67%), survived in 6 cases (33.33%), and had a median OS of 37 (28, 55) months. The difference in group OS was statistically significant (P<0.05). Cox regression analysis showed that high FBG, TG, INS, HOMA-IR, and Cr were all risk factors for postoperative prognosis in patients with renal cell carcinoma (P<0.05). The Pearson correlation analysis results showed that the TyG index was positively correlated with FBG, TG, INS, HOMA-IR, Cr and other indicators (r=0.825, 0.932, 0.841, 0.585, 0.855), and the correlation was significant (P<0.05).

Conclusion

The TyG index is closely related to the postoperative prognosis of patients with renal cell carcinoma, and patients with high TyG index have worse postoperative prognosis.

Key words: Renal cell carcinoma, Postoperative, Triglyceride-glucose index, Prognosis

Guolu Liu, Qian Li, Yijin Wang, Sugui Wang, Hao Hu, Lu Zhang. Relationship between triglyceride-glucose index and postoperative prognosis of patients with renal cell carcinoma[J]. Chinese Journal of Endourology(Electronic Edition), 2025, 19(04): 492-497.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhqjmnmwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3253.2025.04.016

https://zhqjmnmwkzz.cma-cmc.com.cn/EN/Y2025/V19/I04/492

Figures/Tables 6

References 20

[1]	Shi H, Guo F, Zheng K, et al. Triglyceride-glucose index (TyG index) and endometrial carcinoma risk: a retrospective cohort study[J]. Int J Gynaecol Obstet, 2024, 164(1): 298-304. DOI: 10.1002/ijgo.15038.
[2]	Preveden T, Veres B, Ruzic M, et al. Triglyceride-glucose index and hepatic steatosis index for the assessment of liver steatosis in HCV patients[J]. Minerva Gastroenterol (Torino), 2023, 69(2): 254-260. DOI: 10.23736/S2724-5985.22.03168-0.
[3]	Song Y, Jiang L, Han Y, et al. Triglyceride-glucose index and glycemic dynamics in pancreatic ductal adenocarcinoma: implications for disease progression and prognosis[J]. J Transl Med, 2024, 22(1): 708. DOI: 10.1186/s12967-024-05524-w.
[4]	Gan LL, Xia C, Zhu X, et al. Predictive value of angiopoietin-like protein 8 in metabolic dysfunction-associated fatty liver disease and its progression: a case-control study[J]. World J Diabetes, 2024, 15(3): 418-428. DOI: 10.4239/wjd.v15.i3.418.
[5]	唐世英, 刘茁, 赵勋, 等. 术前AST和AST/ALT评估非转移性肾细胞癌伴静脉癌栓患者预后的价值[J]. 中华泌尿外科杂志, 2020, 41(7): 497-502. DOI: 10.3760/cma.j.cn112330-20200221-00103.
[6]	中华医学会病理学分会泌尿与男性生殖系统疾病病理专家组. 肾细胞癌分子病理研究进展及检测专家共识(2020版)[J]. 中华病理学杂志, 2020, 49(12): 1232-1241. DOI: 10.3760/cma.j.cn112151-20200810-00637.
[7]	Liu GM, Zhu WB, Xu JW. Triglyceride-glucose index predicts postoperative overall survival in hepatocellular carcinoma: a retrospective cohort study[J]. Discov Oncol, 2024, 15(1): 651. DOI: 10.1007/s12672-024-01541-9.
[8]	兰瑾涛, 童行, 印胡滨, 等. 腹腔镜保留肾单位肾肿瘤切除术对肾细胞癌患者肾功能和预后的影响[J]. 重庆医科大学学报, 2023, 48(8): 995-999. DOI: 10.13406/j.cnki.cyxb.003315.
[9]	Bahadoram S, Davoodi M, Hassanzadeh S, et al. Renal cell carcinoma: an overview of the epidemiology, diagnosis, and treatment[J]. G Ital Nefrol, 2022, 39(3): 2022-vol3.
[10]	张有余, 韦峰, 刘忠军, 等. 肾透明细胞癌脊柱转移的手术效果及生存期相关因素研究[J]. 中国脊柱脊髓杂志, 2023, 33(4): 300-307.
[11]	Lobo J, Ohashi R, Amin MB, et al. WHO 2022 landscape of papillary and chromophobe renal cell carcinoma[J]. Histopathology, 2022, 81(4): 426-438. DOI: 10.1111/his.14700.
[12]	朱国栋. 局部及局部进展期高危肾细胞癌患者术后复发、早期进展及总生存期的临床预测模型[J]. 现代泌尿外科杂志, 2021, 26(8): 706-707.
[13]	Navani V, Heng DYC. Immunotherapy in renal cell carcinoma[J]. Lancet Oncol, 2023, 24(11): 1164-1166. DOI: 10.1016/S1470-2045(23)00473-4.
[14]	Dogan R, Kucuk RB, Tugrul S, et al. Evaluation of triglyceride-glucose index elevation as a biomarker and risk factor in laryngeal squamous cell carcinoma[J]. Clin Otolaryngol, 2024, 49(6): 742-747. DOI: 10.1111/coa.14197.
[15]	Powles T, Albiges L, Bex A, et al. Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up[J]. Ann Oncol, 2024, 35(8): 692-706. DOI: 10.1016/j.annonc.2024.05.537.
[16]	Yang SH, He YS, Zheng SQ, et al. Triglyceride-glucose index is an independent risk factor for hepatocellular carcinoma development in patients with HBV-related liver cirrhosis[J]. J Hepatocell Carcinoma, 2024, 11: 737-746. DOI: 10.2147/JHC.S454037.
[17]	Guo S, Zhao Y, Jiang Y, et al. Increased pretreatment triglyceride glucose-body mass index associated with poor prognosis in patients with advanced non-small cell lung cancer[J]. Clin Nutr ESPEN, 2024, 59: 412-421. DOI: 10.1016/j.clnesp.2023.12.018.
[18]	Okamura T, Hashimoto Y, Hamaguchi M, et al. Triglyceride-glucose index (TyG index) is a predictor of incident colorectal cancer: a population-based longitudinal study[J]. BMC Endocr Disord, 2020, 20(1): 113. DOI: 10.1186/s12902-020-00581-w.
[19]	Nguyen A, Khafagy R, Hashemy H, et al. Investigating the association between fasting insulin, erythrocytosis and HbA1c through Mendelian randomization and observational analyses[J]. Front Endocrinol (Lausanne), 2023, 14: 1146099. DOI: 10.3389/fendo.2023.1146099.
[20]	Yang C, Cheng W, Plum PS, et al. Association between four insulin resistance surrogates and the risk of esophageal cancer: a prospective cohort study using the UK Biobank[J]. J Cancer Res Clin Oncol, 2024, 150(8): 399. DOI: 10.1007/s00432-024-05919-8.

项目	数值
年龄[岁，(±s)]	49±8
性别[例(%)]
男	55（50.93）
女	53（49.07）
体质量指数[kg/m²，(±s)]	19.43±1.42
R.E.N.A.L.评分[分，(±s)]	7.6±1.4
肿瘤直径[cm，(±s)]	9.4±3.3
肿瘤分期[例(%)]
T_1b期	33（30.56）
T₂期	25（23.15）
T₃期	22（20.37）
T₄期	28（25.92）

项目	数值
年龄[岁，(±s)]	49±8
性别[例(%)]
男	55（50.93）
女	53（49.07）
体质量指数[kg/m²，(±s)]	19.43±1.42
R.E.N.A.L.评分[分，(±s)]	7.6±1.4
肿瘤直径[cm，(±s)]	9.4±3.3
肿瘤分期[例(%)]
T_1b期	33（30.56）
T₂期	25（23.15）
T₃期	22（20.37）
T₄期	28（25.92）

项目	低TyG指数组（n=51）	中TyG组指数（n=39）	高TyG指数组（n=18）	统计值	P值
性别[例(%)]
男	29（56.86）	18（46.15）	8（44.44）	χ²=1.377	0.502
女	22（43.14）	21（53.85）	10（55.56）
年龄[岁，(±s)]	48±7	50±8	52±10	F=1.796	0.171
体质量指数[kg/m²，(±s)]	19.2±1.5	19.4±1.2	19.6±1.4	F=0.639	0.530
肿瘤位置[例(%)]
肾实质内	19（37.25）	15（38.46）	8（44.44）	χ²=0.428	0.980
肾盂内	21（41.18）	16（41.03）	6（33.33）
肾周	11（21.57）	8（20.51）	4（22.22）
肿瘤直径[cm，(±s)]	9.6±3.4	9.4±3.4	9.2±3.3	F=0.096	0.909
肿瘤分期[例(%)]
T_1b期	15（29.41）	12（30.77）	6（33.33）	χ²=0.685	0.995
T₂期	13（25.49）	8（20.51）	4（22.22）
T₃期	11（21.57）	8（20.51）	3（16.67）
T₄期	12（23.53）	11（28.21）	5（27.78）
FBG[mmol/L，(±s)]	6.3±1.5	8.7±1.4	9.4±1.5	F=142.376	<0.001
HbA1c[%，(±s)]	6.5±1.6	6.6±1.3	7.0±1.5	F=0.604	0.549
TG[mmol/L，(±s)]	0.94±0.21	1.79±0.26	2.69±0.33	F=353.447	<0.001
TC[mmol/L，(±s)]	7.6±1.7	7.9±1.3	8.3±1.3	F=1.275	0.284
LDL-C[mmol/L，(±s)]	5.4±1.4	5.5±1.2	6.0±1.3	F=1.372	0.258
INS[mIU/L，(±s)]	21±3	29±5	37±3	F=118.861	<0.001
HOMA-IR(±s)	2.5±1.3	4.3±1.2	5.3±1.3	F=40.709	<0.001
CRP[mg/L，(±s)]	24.4±2.4	25.5±4.4	26.4±5.4	F=2.224	0.113
Cr[μmol/L，(±s)]	126±5	133±5	157±3	F=286.398	<0.001
BUN[mmol/L，(±s)]	10.6±3.5	11.5±2.4	11.5±2.6	F=1.125	0.329
CEA[ug/L，(±s)]	9.7±2.4	9.9±2.6	10.2±3.5	F=0.179	0.757

项目	低TyG指数组（n=51）	中TyG组指数（n=39）	高TyG指数组（n=18）	统计值	P值
性别[例(%)]
男	29（56.86）	18（46.15）	8（44.44）	χ²=1.377	0.502
女	22（43.14）	21（53.85）	10（55.56）
年龄[岁，(±s)]	48±7	50±8	52±10	F=1.796	0.171
体质量指数[kg/m²，(±s)]	19.2±1.5	19.4±1.2	19.6±1.4	F=0.639	0.530
肿瘤位置[例(%)]
肾实质内	19（37.25）	15（38.46）	8（44.44）	χ²=0.428	0.980
肾盂内	21（41.18）	16（41.03）	6（33.33）
肾周	11（21.57）	8（20.51）	4（22.22）
肿瘤直径[cm，(±s)]	9.6±3.4	9.4±3.4	9.2±3.3	F=0.096	0.909
肿瘤分期[例(%)]
T_1b期	15（29.41）	12（30.77）	6（33.33）	χ²=0.685	0.995
T₂期	13（25.49）	8（20.51）	4（22.22）
T₃期	11（21.57）	8（20.51）	3（16.67）
T₄期	12（23.53）	11（28.21）	5（27.78）
FBG[mmol/L，(±s)]	6.3±1.5	8.7±1.4	9.4±1.5	F=142.376	<0.001
HbA1c[%，(±s)]	6.5±1.6	6.6±1.3	7.0±1.5	F=0.604	0.549
TG[mmol/L，(±s)]	0.94±0.21	1.79±0.26	2.69±0.33	F=353.447	<0.001
TC[mmol/L，(±s)]	7.6±1.7	7.9±1.3	8.3±1.3	F=1.275	0.284
LDL-C[mmol/L，(±s)]	5.4±1.4	5.5±1.2	6.0±1.3	F=1.372	0.258
INS[mIU/L，(±s)]	21±3	29±5	37±3	F=118.861	<0.001
HOMA-IR(±s)	2.5±1.3	4.3±1.2	5.3±1.3	F=40.709	<0.001
CRP[mg/L，(±s)]	24.4±2.4	25.5±4.4	26.4±5.4	F=2.224	0.113
Cr[μmol/L，(±s)]	126±5	133±5	157±3	F=286.398	<0.001
BUN[mmol/L，(±s)]	10.6±3.5	11.5±2.4	11.5±2.6	F=1.125	0.329
CEA[ug/L，(±s)]	9.7±2.4	9.9±2.6	10.2±3.5	F=0.179	0.757

组别	例数	FBG(mmol/L)	TG(mmol/L)	INS(mIU/L)	HOMA-IR	Cr(μmol/L)
死亡组	28	9.5±2.5	2.97±0.22	39.6±5.2	7.8±2.5	169±15
存活组	80	5.4±2.5	1.22±0.29	23.7±2.4	3.9±1.5	132±16
t值		7.549	29.100	21.560	10.016	10.253
P值		<0.001	<0.001	<0.001	<0.001	<0.001

Please choose a citation manager

Content to export